JNCE News and Press, Jounce Therapeutics Inc. From 05/23/22

Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech valuations have re-rated. Following are the stocks which saw their PT lowered: Gene editing com...

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate at the following ...

Jounce Therapeutics (NASDAQ:JNCE) is down 19%, Wednesday, after Robert W. Baird downgraded its rating to Neutral from Outperform over incrementally more cautious stance on biotech's priority asset JTX-8064, a monoclonal antibody undergoing studies for patients with a certain type of...

Jounce Therapeutics, Inc. (JNCE) Q1 2022 Earnings Conference Call May 05, 2022, 08:00 ET Company Participants Eric Laub - VP, IR Richard Murray - President, CEO & Director Elizabeth Trehu - Chief Medical Officer Kimberlee Drapkin - Chief Financial Officer & Treasurer Dmitri Wiederscha...

Raymond James analysts have raised their rating on Jounce Therapeutics (NASDAQ:JNCE) to Strong Buy from Outperform after the clinical-stage biotech reported its 1Q 2022 earnings, in which the management highlighted the progress in its pipeline. The analysts led by Steven Seedhouse argues...

Gainers: ChemoCentryx (CCXI) +19%. iRhythm Technologies (IRTC) +16%. Jounce Therapeutics (JNCE) +15%. Grifols (GRFS) +9%. Sensus Healthcare (SRTS) +8%. Losers: Joint (JYNT) -46%. Endo International (ENDP) -34%. Guardant Health (GH) -26%. Gain ...

Jounce Therapeutics press release (NASDAQ:JNCE): Q1 GAAP EPS of -$0.72 misses by $0.15. Gross cash burn on operating expenses and capital expenditures for the full year 2022 is expected to be approximately $115.0 million to $130.0 million. Given the strength of its balance sheet, Jounce expec...

- Two combination cohorts met initial response criteria for continued expansion in INNATE trial of JTX-8064; on track to present data on at least 60 Phase 2 patients across multiple cohorts in 2H2022 - - Target enrollment achieved in SELECT trial of vopratelimab in combination w...

Jounce Therapeutics (NASDAQ:JNCE) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is -$0.56 and the consensus Revenue Estimate is $0.68M (-55.8% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 3 down...

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2022 financial result...